Video

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Deepa Jagadeesh, MD, associate staff, Department of Hematologic Oncology and Blood Disorders, Lymphoma and Bone Marrow Transplant Programs, Cleveland Clinic, discusses unmet needs in aggressive and rare lymphoma subtypes.

Most available therapies in relapsed/refractory peripheral T-cell lymphoma (PTCL) elicit response rates around 30%, which represents a major unmet need in the space, Jagadeesh says.

Notably, duvelisib (Copiktra) has demonstrated slightly higher historical response rates in patients with relapsed/refractory PTCL, Jagadeesh says. Moreover, brentuximab vedotin (Adcetris) has shown encouraging response rates in patients with anaplastic large cell lymphoma.

 Despite this, few treatment options are available for patients with rare lymphoma subtypes because it is difficult to enroll them onto clinical trials, Jagadeesh explains. This can be true even if the patient is eligible for enrollment.

 As such, additional data are needed to draw meaningful conclusions regarding the efficacy of novel therapies in this space, Jagadeesh concludes.

Related Videos
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Martin Dreyling, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Dr Shreenivas on the Association Between MUC1 and CLDN18 in GI Cancers
David Samuel Dicapua Siegel, MD
Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Andrew Ip, MD
Yousef Zakharia, MD
Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.